List of Diagnostics Companies in Singapore - 8

4baseCare, an Illumina-backed Company* headquartered in Singapore, is engaged in developing cutting-edge Precision Oncology Solutions using Advanced Genomics and Next-Gen digital health technology. Taking into consideration that the clinical outcome could significantly vary across different populations, we have developed a unique set of indigenous comprehensive cancer gene panels that enables oncologists to choose the optimal precision therapies for their patients. Our coveted 🧬genomic testing portfolio assesses the tumour genomic alterations by NGS from Tissue or Liquid biopsy for Somatic Mutation Analysis and Germline Mutation Testing for Hereditary and Familial Cancer from peripheral blood to personalize patient care in Oncology. 4baseCare is backed by a highly experienced Advisory board who are leaders in genomics and technology. Among them is Lip Bu Tan, Chairman of Walden International and advisor to Yali Capital, which has invested in 4baseCare. Also on the board is Francis deSouza, a Silicon Valley tech veteran and former CEO of Illumina, who brings over 30 years of expertise in genomics, technology, and healthcare. Milestones - 4baseCare’s journey has been marked by significant milestones in both funding and growth. The company has raised $6 Million in Series A funding led by Yali Capital with participation from Mathew Cyriac. In March 2021, 4baseCare had raised $2 Million in led by Mount Judi Ventures, growX ventures, Season Two Ventures, First In Ventures, and other angel investors. 4baseCare’s test has made a significant impact in Southeast Asia, with over 10,000 cancer patients taking the test. 4baseCare has collaborations with more than 300 oncologists in India. This growing network with oncologists and leading hospitals in India ensures that more patients are able to opt for personalized cancer care.

Aevice Health Pte Ltd is a Singapore-based MedTech spin-off from Nanyang Technological University at the forefront of addressing chronic respiratory disease, one of the generation's biggest healthcare challenges. The company's non-invasive wearable devices enable the early detection of cardiopulmonary abnormalities remotely and in real-time, so that patients can receive fast and targeted care from the ease of their homes. Clinicians can also gain insights into their patients' health and track their responses to treatment plans easily from the Aevice analytical platform. In Aevice Health, our mission is to drive medical innovations that transform healthcare, improve outcomes and empower lives. More information about the company can be found at www.aevice.com.

Credo Diagnostics Biomedical develops, manufactures, and commercializes innovative, cost-effective, and rapid Molecular Diagnostic solutions at the Point-of-Care (POC) in the areas of human infectious diseases and animal health. At Credo Diagnostics Biomedical, we are conscious of the necessity to simplify processes and accelerate molecular testing at lower costs. We believe that effective rapid POC Molecular Diagnostics will redefine healthcare for both human and veterinary clinical management. By providing the right information, at the right time, and to the right people, we can improve the lives of billions of people and animals around the world. For any inquiries, please contact us at: service@credodxbiomed.com

Entrepreneur led and science backed, 𝐈𝐍𝐄𝐗 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐞 is one of Asia’s fastest growing molecular diagnostics developers and medical laboratory operators. Founded by veteran maternal fetal medicine specialists, INEX is uniquely positioned to identify and address clinically unmet needs within the fetal health and women’s oncology landscape, with a broad commercial portfolio of validated tests and 49 key patents. Through our wholly owned subsidiary iGene Laboratory Pte Ltd, INEX operates a state of the art Next Generation Sequencing Laboratory that provides diagnostic testing, clinical research (CRO) and infectious testing services. The company has been recognised globally with a number of accolades and awards including from Frost & Sullivan, the World Intellectual Property Organisation (WIPO), The Straits Times – Singapore’s Fastest Growing Companies, the Financial Times ranking of 500 of Asia Pacific’s Fastest Growing Companies and the Business Times KPMG Enterprise 50 award, recognising the 50 most enterprising Singapore companies. For more information please visit: www.inex.sg

JN Medsys is a people-centered life science company driven by the desire to make complex genomic tools accessible to more people. Through a relentless commitment to innovation, we aim to deliver simplified solutions that achieve improved performance at better affordability. The Clarity digital PCR is the epitome of this vision. It brings digital PCR analysis to the next level by significantly reducing its preparation time and simplifying its workflow. With digital PCR this fast and easy, the choice is now clear. Choose Clarity for your digital PCR needs.

Mirxes is a Singapore-headquartered biotechnology company whose mission is to save lives through early, actionable, and personalized diagnoses across the care continuum. We are Asia-centered, starting with Southeast Asia, and have global ambitions. We have research, development, manufacturing, and clinical diagnostic operations in Singapore, USA, Japan, and China. We have sales and distribution networks worldwide. Our flagship product is GASTROClear, the world’s first molecular blood test for early detection of gastric cancer, able to detect around 90% of patients with Stage I and II cancers. We continue to build a comprehensive cancer portfolio with early detection tests for lung and thyroid cancer (2022), colorectal and breast cancer (2023), liver and ovarian cancer (2024). We are concurrently building a precision oncology portfolio to provide clinical insights for the complete patient journey. MiRXES was spun off from A*STAR’s Bioprocessing Technology Institute in 2014 to commercialize an industry-leading qPCR-based technology for microRNA detection. Our ID3EAL discovery tool and workflow has been adopted by top academic and industry partners globally and is backed by the world’s first industry standard for microRNA-base diagnostics. Our versatile platform technology and capabilities have broad applications in the discovery of biomarkers and diagnosis of diseases. We are starting with early cancer detection, but we will also be addressing unmet clinical needs in cardiovascular, metabolic, and infectious diseases. We responded to COVID-19 by leveraging our capabilities to mass produce and distribute over 5 million units of the Fortitude COVID-19 RT-PCR test. This made-in-Singapore diagnostic test, developed by A*STAR and Tan Tock Seng Hospital, has been deployed in 13 Singapore hospitals and clinical labs and exported to over 45 countries worldwide. Post-COVID, we will leverage this network to commercialize multi-cancer early detection tests.

We are a molecular life science company dedicated to advancing human health through innovation. By designing and building breakthrough molecular platforms that are both accessible and best-in-class, One BioMed is providing biomedical researchers and clinicians with unprecedented access to cutting-edge tools.

SDT Molecular is a Singapore-based company with the vision of bringing advanced technologies and innovative products to healthcare professionals, hospitals and clinical laboratories.